DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Learn more

CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Berkeley Heights, NJ – April 22, 2019 – CorMedix Inc. (NYSE American: CRMD), a
biopharmaceutical company focused on developing and commercializing therapeutic products
for the prevention and treatment of infectious and inflammatory disease, today announced
publication online of a pre-clinical data abstract at the upcoming annual meeting of the American
Society of Clinical Oncology (ASCO), a major educational and scientific event in oncology being
held in Chicago, IL on May 31 through June 4, 2019.

The abstract, entitled “Effective targeted antitumor activity of the antimicrobial agent taurolidine
against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation, and tumor
xenograft studies” reviews a pre-clinical study in a mouse model of neuroblastoma led by Dr. Aru
Narendran, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology, Cumming
School of Medicine, University of Calgary. ASCO will release abstracts online on May 15, 2019.

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing
therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic
antimicrobial solution designed to prevent costly and dangerous bloodstream infections
associated with the use of central venous catheters, currently in Phase 3 development for
patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system
approximately $6 billion annually and contribute significantly to increased morbidity and
mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease
Product, which provides the potential for priority review of a marketing application by FDA and
allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is
already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix
is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices,
with active programs in surgical sutures and meshes, and topical hydrogels. The company is also
working with top-tier researchers to develop taurolidine-based therapies for rare pediatric
cancers. For more information, visit: www.cormedix.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding management’s expectations,
beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future
revenues and projected costs should be considered forward-looking. Readers are cautioned that
actual results may differ materially from projections or estimates due to a variety of important
factors, including: relying on preclinical results that may not be indicative of success in clinical
trials and might not be replicated in any subsequent studies or trials; the risks and uncertainties
associated with research for additional uses for taurolidine; risks relating to the effect of the
recently-effected reverse stock split on the Company’s stock price and its overall market
capitalization; the resources needed to terminate the Phase 3 trial and the costs and time needed
to submit a new drug application to the FDA; the risks and uncertainties associated with
CorMedix’s ability to manage its limited cash resources and the impact on current, planned or
future research, including the continued development of Neutrolin;obtaining additional financing
to support CorMedix’s research and development and clinical activities and operations; risks
related to obtaining FDA approval of the new drug application for Neutrolin; and the ability to
retain and hire necessary personnel to staff our operations appropriately. These and other risks
are described in greater detail in CorMedix’s filings with the SEC, copies of which are available
free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix
may not actually achieve the goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements. CorMedix assumes no obligation
and does not intend to update these forward-looking statements, except as required by law.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
617-535-7746